Literature DB >> 3528618

Use of beta 2 microglobulin to diagnose tubulo-interstitial renal lesions in children.

R J Portman, J M Kissane, A M Robson.   

Abstract

Fractional excretion (FE) of beta 2 microglobulin (beta 2M) was studied in children with glomerular (N = 114), tubular (N = 50) or other (N = 18) renal diseases. FE-beta 2M (normal less than 0.36%) was significantly (P less than 0.001) lower in glomerular diseases (mean 0.104%) than in tubular lesions (mean 4.27%). Unexpectedly, several patients with glomerular disease were found to have increased values for FE-beta 2M. To determine whether this was due to a tubular component in a primary glomerular disease process, FE-beta 2M was measured in 30 children with various glomerulopathies who underwent renal biopsy. Thirteen of these patients had tubulo-interstitial lesions in addition to their glomerular disease. FE-beta 2M in these patients averaged 3.76% (range 0.14 to 44.6%); only two results were normal. Mean FE-beta 2M in the 17 patients without biopsy evidence of tubulo-interstitial disease was 0.063% (range 0.02 to 0.34%); all values were in the normal range. The types of glomerular diseases in the two groups of patients were similar. Patients with a glomerular lesion complicated by tubulo-interstitial lesions had a poorer prognosis than did those with a pure glomerular disease. The high incidence of tubulo-interstitial lesions in patients with glomerular diseases was unexpected. Our data demonstrates that FE-beta 2M represents a reliable non-invasive method to diagnose such involvement. Measurements of beta 2M also provide a convenient method to follow the course and response to treatment of renal tubular injury.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528618     DOI: 10.1038/ki.1986.156

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Renal function and kidney size in glycogen storage disease type I.

Authors:  W C Reitsma-Bierens; G P Smit; J A Troelstra
Journal:  Pediatr Nephrol       Date:  1992-05       Impact factor: 3.714

3.  Urinary beta 2-microglobulin as a marker for vesicoureteral reflux.

Authors:  F K Assadi
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin.

Authors:  J E Hopper; W Sequeira; J Martellotto; E Papagiannes; L Perna; J L Skosey
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

5.  Renal tubular dysfunction in alpha-thalassemia.

Authors:  Achra Sumboonnanonda; Prida Malasit; Voravarn S Tanphaichitr; Sompong Ong-ajyooth; Siripan Petrarat; Arun Vongjirad
Journal:  Pediatr Nephrol       Date:  2003-02-26       Impact factor: 3.714

6.  Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  J Pomerleau; M Verdy; D R Garrel; M H Nadeau
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

7.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

8.  Ammonium urate nephrolithiasis in a variant of Bartter's syndrome with intact renal tubular function.

Authors:  G Yasuda; R Zierer; A Maio; H Shioniri; M Ishii; S Umemura
Journal:  Clin Investig       Date:  1994-05

Review 9.  Low molecular weight proteins in children with renal disease.

Authors:  P A Tomlinson
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

10.  Follow-up of renal function and urinary protein excretion in childhood IgA nephropathy.

Authors:  U B Berg; U C Widstam-Attorps
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.